BOTHELL, Wash. & LOS ANGELES--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) today announced data from fifteen presentations by the company and its collaborators at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) demonstrating preclinical advances with its proprietary antibody-drug conjugate (ADC) technology and cancer product pipeline.
